Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of 556.43 million. The enterprise value is 772.22 million.
| Market Cap | 556.43M |
| Enterprise Value | 772.22M |
Important Dates
The last earnings date was Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 90.49M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.28% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 73.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.57 |
| PB Ratio | 1.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -34.05 |
| EV / Sales | 3.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -11.83 |
Financial Position
The company has a current ratio of 3.62, with a Debt / Equity ratio of 0.98.
| Current Ratio | 3.62 |
| Quick Ratio | 2.81 |
| Debt / Equity | 0.98 |
| Debt / EBITDA | n/a |
| Debt / FCF | -6.87 |
| Interest Coverage | -3.03 |
Financial Efficiency
Return on equity (ROE) is -4.85% and return on invested capital (ROIC) is -2.64%.
| Return on Equity (ROE) | -4.85% |
| Return on Assets (ROA) | -2.38% |
| Return on Invested Capital (ROIC) | -2.64% |
| Return on Capital Employed (ROCE) | -4.41% |
| Revenue Per Employee | 556,079 |
| Profits Per Employee | -58,300 |
| Employee Count | 374 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.38 |
Taxes
| Income Tax | -13.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.97% in the last 52 weeks. The beta is 0.29, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -33.97% |
| 50-Day Moving Average | 6.29 |
| 200-Day Moving Average | 6.47 |
| Relative Strength Index (RSI) | 48.40 |
| Average Volume (20 Days) | 279 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of 216.31 million and -22.68 million in losses. Loss per share was -0.25.
| Revenue | 216.31M |
| Gross Profit | 163.66M |
| Operating Income | -39.69M |
| Pretax Income | -36.22M |
| Net Income | -22.68M |
| EBITDA | -10.76M |
| EBIT | -39.69M |
| Loss Per Share | -0.25 |
Balance Sheet
The company has 228.71 million in cash and 448.61 million in debt, giving a net cash position of -219.90 million.
| Cash & Cash Equivalents | 228.71M |
| Total Debt | 448.61M |
| Net Cash | -219.90M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 456.49M |
| Book Value Per Share | 5.04 |
| Working Capital | 269.77M |
Cash Flow
In the last 12 months, operating cash flow was -60.97 million and capital expenditures -4.32 million, giving a free cash flow of -65.28 million.
| Operating Cash Flow | -60.97M |
| Capital Expenditures | -4.32M |
| Free Cash Flow | -65.28M |
| FCF Per Share | n/a |
Margins
Gross margin is 75.66%, with operating and profit margins of -18.35% and -10.48%.
| Gross Margin | 75.66% |
| Operating Margin | -18.35% |
| Pretax Margin | -16.75% |
| Profit Margin | -10.48% |
| EBITDA Margin | -4.97% |
| EBIT Margin | -18.35% |
| FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.28% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.08% |
| FCF Yield | -11.73% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nxera Pharma has an Altman Z-Score of 1.08 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.08 |
| Piotroski F-Score | 3 |